Growth hormone improves growth retardation induced by rapamycin without blocking its antiproliferative and antiangiogenic effects on rat growth plate
- PMID: 22493717
- PMCID: PMC3321024
- DOI: 10.1371/journal.pone.0034788
VSports在线直播 - Growth hormone improves growth retardation induced by rapamycin without blocking its antiproliferative and antiangiogenic effects on rat growth plate
Abstract
Rapamycin, an immunosuppressant agent used in renal transplantation with antitumoral properties, has been reported to impair longitudinal growth in young individuals VSports手机版. As growth hormone (GH) can be used to treat growth retardation in transplanted children, we aimed this study to find out the effect of GH therapy in a model of young rat with growth retardation induced by rapamycin administration. Three groups of 4-week-old rats treated with vehicle (C), daily injections of rapamycin alone (RAPA) or in combination with GH (RGH) at pharmacological doses for 1 week were compared. GH treatment caused a 20% increase in both growth velocity and body length in RGH animals when compared with RAPA group. GH treatment did not increase circulating levels of insulin-like growth factor I, a systemic mediator of GH actions. Instead, GH promoted the maturation and hypertrophy of growth plate chondrocytes, an effect likely related to AKT and ERK1/2 mediated inactivation of GSK3β, increase of glycogen deposits and stabilization of β-catenin. Interestingly, GH did not interfere with the antiproliferative and antiangiogenic activities of rapamycin in the growth plate and did not cause changes in chondrocyte autophagy markers. In summary, these findings indicate that GH administration improves longitudinal growth in rapamycin-treated rats by specifically acting on the process of growth plate chondrocyte hypertrophy but not by counteracting the effects of rapamycin on proliferation and angiogenesis. .
Conflict of interest statement
Figures





References
-
- Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–484. - "VSports最新版本" PubMed
-
- Geissler EK, Schlitt HJ. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int. 2010;78:1075–1079. - PubMed (VSports)
-
- Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation. 2004;77:1319–1326. - PubMed
-
- Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–2281. - PubMed
-
- Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus to replace calcineurin inhibitors? Too early yet. Lancet. 2009;373:1235–1236. - PubMed
Publication types
- V体育平台登录 - Actions
MeSH terms
- Actions (VSports手机版)
- "V体育官网入口" Actions
- Actions (V体育官网)
- "VSports手机版" Actions
- "V体育官网入口" Actions
- VSports app下载 - Actions
- "VSports注册入口" Actions
- "VSports手机版" Actions
- "V体育平台登录" Actions
- "V体育安卓版" Actions
- Actions (V体育官网入口)
- Actions (VSports最新版本)
Substances
- Actions (V体育官网入口)
- Actions (V体育2025版)
- "V体育平台登录" Actions
LinkOut - more resources
Full Text Sources (VSports在线直播)
Molecular Biology Databases
Research Materials
"V体育2025版" Miscellaneous